$125.23
Merck & Co Inc is a pharmaceutical company that develops and sells prescription drugs in various therapeutic areas, including oncology, vaccines, and infectious diseases.
0.47%
Downside
Day's Volatility :0.7%
Upside
0.23%
21.9%
Downside
52 Weeks Volatility :26.51%
Upside
5.91%
Period | Merck & Co. Inc. | |
---|---|---|
3 Months | 5.76% | |
6 Months | 22.92% | |
1 Year | 9.18% | |
3 Years | 61.43% |
Market Capitalization | 316.8B |
Book Value | $14.85 |
Dividend Share | 2.92 |
Dividend Yield | 2.46% |
Earnings Per Share (EPS) | 0.14 |
PE Ratio | 893.29 |
PEG Ratio | 0.1 |
Wall Street Target Price | 137.02 |
Profit Margin | 0.61% |
Operating Margin TTM | 0.08% |
Return On Assets TTM | 2.64% |
Return On Equity TTM | 0.9% |
Revenue TTM | 60.1B |
Revenue Per Share TTM | 23.7 |
Quarterly Revenue Growth YOY | 5.800000000000001% |
Gross Profit TTM | 42.1B |
EBITDA | 8.3B |
Diluted Eps TTM | 0.14 |
Quarterly Earnings Growth YOY | 0.45 |
EPS Estimate Current Year | 8.56 |
EPS Estimate Next Year | 9.77 |
EPS Estimate Current Quarter | 1.96 |
EPS Estimate Next Quarter | 2.1 |
What analysts predicted
Upside of 9.41%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 42.3B | ↑ 5.41% |
Net Income | 6.2B | ↑ 142.21% |
Net Profit Margin | 14.71% | ↑ 8.31% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 46.8B | ↑ 10.75% |
Net Income | 9.8B | ↑ 58.25% |
Net Profit Margin | 21.01% | ↑ 6.3% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 48.0B | ↑ 2.46% |
Net Income | 7.1B | ↓ 28.2% |
Net Profit Margin | 14.72% | ↓ 6.29% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 48.7B | ↑ 1.48% |
Net Income | 13.0B | ↑ 84.65% |
Net Profit Margin | 26.79% | ↑ 12.07% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 59.3B | ↑ 21.72% |
Net Income | 14.5B | ↑ 11.27% |
Net Profit Margin | 24.49% | ↓ 2.3% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 59.9B | ↑ 0.99% |
Net Income | 365.0M | ↓ 97.49% |
Net Profit Margin | 0.61% | ↓ 23.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.8B | ↓ 7.55% |
Net Income | 3.0B | ↓ 7.11% |
Net Profit Margin | 21.81% | ↑ 0.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.5B | ↑ 4.75% |
Net Income | 2.8B | ↓ 6.5% |
Net Profit Margin | 19.47% | ↓ 2.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.0B | ↑ 3.78% |
Net Income | -6.0B | ↓ 311.8% |
Net Profit Margin | -39.74% | ↓ 59.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.0B | ↑ 6.17% |
Net Income | 4.7B | ↓ 179.41% |
Net Profit Margin | 29.73% | ↑ 69.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.6B | ↓ 8.34% |
Net Income | -1.2B | ↓ 125.84% |
Net Profit Margin | -8.38% | ↓ 38.11% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 14.6B | ↑ 0.0% |
Net Income | -1.2B | ↑ 0.0% |
Net Profit Margin | -8.38% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 82.6B | ↓ 5.96% |
Total Liabilities | 55.8B | ↑ 4.6% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 84.4B | ↑ 2.13% |
Total Liabilities | 58.4B | ↑ 4.74% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 91.6B | ↑ 8.52% |
Total Liabilities | 66.2B | ↑ 13.34% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 105.7B | ↑ 15.4% |
Total Liabilities | 67.4B | ↑ 1.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 109.2B | ↑ 3.28% |
Total Liabilities | 63.1B | ↓ 6.43% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 106.7B | ↓ 2.28% |
Total Liabilities | 69.0B | ↑ 9.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 109.2B | ↑ 1.94% |
Total Liabilities | 63.1B | ↑ 0.87% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 107.8B | ↓ 1.25% |
Total Liabilities | 60.9B | ↓ 3.5% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 104.5B | ↓ 3.09% |
Total Liabilities | 65.7B | ↑ 7.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.7B | ↑ 2.16% |
Total Liabilities | 65.4B | ↓ 0.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.7B | ↓ 0.05% |
Total Liabilities | 69.0B | ↑ 5.52% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 106.7B | ↑ 0.0% |
Total Liabilities | 69.0B | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.9B | ↑ 69.41% |
Investing Cash Flow | 4.3B | ↑ 61.03% |
Financing Cash Flow | -13.2B | ↑ 31.52% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.4B | ↑ 23.05% |
Investing Cash Flow | -2.6B | ↓ 160.94% |
Financing Cash Flow | -8.9B | ↓ 32.67% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.3B | ↓ 23.71% |
Investing Cash Flow | -9.4B | ↑ 259.19% |
Financing Cash Flow | -2.8B | ↓ 68.04% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.1B | ↑ 37.61% |
Investing Cash Flow | -16.4B | ↑ 73.9% |
Financing Cash Flow | 2.6B | ↓ 191.56% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 19.1B | ↑ 35.34% |
Investing Cash Flow | -5.0B | ↓ 69.79% |
Financing Cash Flow | -9.1B | ↓ 451.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.4B | ↓ 20.92% |
Investing Cash Flow | -1.7B | ↑ 81.7% |
Financing Cash Flow | -1.6B | ↓ 42.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.3B | ↓ 69.77% |
Investing Cash Flow | -2.4B | ↑ 34.95% |
Financing Cash Flow | -2.1B | ↑ 32.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.7B | ↑ 176.62% |
Investing Cash Flow | -11.4B | ↑ 385.08% |
Financing Cash Flow | 3.8B | ↓ 282.96% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.7B | ↑ 108.34% |
Investing Cash Flow | -14.1B | ↑ 23.53% |
Financing Cash Flow | -4.3B | ↓ 213.6% |
Sell
Neutral
Buy
Merck & Co. Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Merck & Co. Inc. | 3.24% | 22.92% | 9.18% | 61.43% | 71.29% |
Eli Lilly And Company | -2.85% | 23.64% | 102.65% | 295.89% | 550.19% |
Johnson & Johnson | -7.65% | -5.21% | -10.09% | -11.01% | 5.27% |
Abbvie Inc | -7.98% | 10.03% | 2.92% | 51.23% | 111.74% |
Pfizer Inc. | -8.3% | -18.5% | -36.83% | -34.7% | -34.79% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Merck & Co. Inc. | 893.29 | 893.29 | 0.1 | 8.56 | 0.01 | 0.03 | 0.02 | 14.85 |
Eli Lilly And Company | 128.31 | 128.31 | 1.43 | 12.51 | 0.48 | 0.12 | 0.01 | 11.98 |
Johnson & Johnson | 27.78 | 27.78 | 0.89 | 10.65 | 0.18 | 0.08 | 0.03 | 28.57 |
Abbvie Inc | 59.98 | 59.98 | 0.45 | 11.11 | 0.35 | 0.08 | 0.04 | 5.87 |
Pfizer Inc. | 69.43 | 69.43 | 0.26 | 2.21 | 0.02 | 0.02 | 0.07 | 15.77 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Merck & Co. Inc. | Buy | $316.8B | 71.29% | 893.29 | 0.61% |
Eli Lilly And Company | Buy | $713.8B | 550.19% | 128.31 | 15.36% |
Johnson & Johnson | Hold | $348.1B | 5.27% | 27.78 | 41.28% |
Abbvie Inc | Buy | $287.8B | 111.74% | 59.98 | 8.95% |
Pfizer Inc. | Buy | $145.5B | -34.79% | 69.43 | 3.62% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Wellington Management Company LLP
Geode Capital Management, LLC
FMR Inc
In the quarter ending March,2024. Merck & Co. Inc. has declared dividend of $0.77
Read MoreMerck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $316.78 Billion. It has a P.E ratio of 867.89. The shares of Merck & Co. Inc. are trading at $125.37. .
Organization | Merck & Co. Inc. |
Employees | 70000 |
CEO | Mr. Robert M. Davis J.D. |
Industry | Health Technology |